Brain Protein May Help Assess Recovery Time Following Concussion
|
By LabMedica International staff writers Posted on 17 Jan 2017 |

Image: A diagram of the forces on the brain in a coup-contrecoup concussion injury (Image courtesy of Wikimedia).
An initial study of blood samples from athletes has indicated that elevated levels of the brain protein tau following a sport-related concussion are associated with a longer recovery period and delayed return-to-play (RTP), suggesting that tau may serve as a marker to help physicians determine an athlete’s recovery status and RTP readiness.
Despite the 3.8 million sports-related concussions that occur annually in the United States, there are no objective tools to confirm when an athlete is ready to resume play. Returning to play too early, before the brain has healed, increases an athlete’s risk of long-term physical and cognitive problems, especially if he or she sustains another concussion. Currently, physicians and trainers must make RTP decisions based on an athlete’s subjective, self-reported symptoms and their performance on standardized tests of memory and attention.
A research team led by Jessica Gill, RN, PhD of National Institute of Nursing Research (NINR) at National Institutes of Health (NIH) and Jeffrey Bazarian, MD, MPH, of University of Rochester Medical Center evaluated changes in tau in 46 Division I and III college athletes who experienced a concussion. Tau (which plays a role in the development of chronic traumatic encephalopathy (CTE), frontotemporal dementia, and Alzheimer’s disease) was measured by immunoassay of preseason blood plasma samples and again within 6 hours following concussion. The assay employed an ultra-sensitive digital-array technology that uses a single molecule enzyme-linked immunoarray (Simoa, by Quanterix), enabling detection of single protein molecules.
The athletes – a mix of soccer, football, basketball, hockey and lacrosse players from the University of Rochester and Rochester Institute of Technology – were divided into 2 groups based on recovery time. Athletes in the “long RTP” group took more than 10 days to RTP following concussion, while athletes in the “short RTP” group took less than 10 days to return to their sport.
Individuals in the long RTP group had higher levels of tau in their blood 6 hours after concussion compared to those in the short RTP group. Long RTP athletes also exhibited a jump in tau from preseason levels compared to their short RTP counterparts. Statistical analyses showed that higher blood tau concentrations 6 hours post-concussion consistently predicted that an athlete would take more than 10 days to resume play.
“This study suggests that tau may be a useful biomarker for identifying athletes who may take longer to recover after a concussion,” said Prof. Bazarian, “Athletes are typically eager to get back to play as soon as possible and may tell doctors that they’re better even when they’re not. Tau is an unbiased measurement that can’t be gamed, athletes can’t fake it. It may be that tau combined with current clinical assessments could help us make more informed RTP decisions and prevent players from going back to a contact sport when their brains are still healing.”
The study included both male and female athletes and showed that tau-related changes occurred in both genders across a variety of sports. The team found significant differences based on sex: women made up 61% of the long RTP group, but only 28% of the short RTP group. Prof. Bazarian said this isn’t surprising – it is well established that females take longer to recover following concussion than males.
The researchers acknowledge that the study is limited by its small size and that more research is needed to determine if tau can be established as a biomarker of concussion severity and/or recovery. Next steps include getting blood samples from athletes immediately following a concussion to see if the relationship between tau and RTP observed in the study holds true also on the sideline in the first few minutes following a head hit.
The study, by Gill J et al, was published in the January 6, 2017, issue of the journal Neurology.
Despite the 3.8 million sports-related concussions that occur annually in the United States, there are no objective tools to confirm when an athlete is ready to resume play. Returning to play too early, before the brain has healed, increases an athlete’s risk of long-term physical and cognitive problems, especially if he or she sustains another concussion. Currently, physicians and trainers must make RTP decisions based on an athlete’s subjective, self-reported symptoms and their performance on standardized tests of memory and attention.
A research team led by Jessica Gill, RN, PhD of National Institute of Nursing Research (NINR) at National Institutes of Health (NIH) and Jeffrey Bazarian, MD, MPH, of University of Rochester Medical Center evaluated changes in tau in 46 Division I and III college athletes who experienced a concussion. Tau (which plays a role in the development of chronic traumatic encephalopathy (CTE), frontotemporal dementia, and Alzheimer’s disease) was measured by immunoassay of preseason blood plasma samples and again within 6 hours following concussion. The assay employed an ultra-sensitive digital-array technology that uses a single molecule enzyme-linked immunoarray (Simoa, by Quanterix), enabling detection of single protein molecules.
The athletes – a mix of soccer, football, basketball, hockey and lacrosse players from the University of Rochester and Rochester Institute of Technology – were divided into 2 groups based on recovery time. Athletes in the “long RTP” group took more than 10 days to RTP following concussion, while athletes in the “short RTP” group took less than 10 days to return to their sport.
Individuals in the long RTP group had higher levels of tau in their blood 6 hours after concussion compared to those in the short RTP group. Long RTP athletes also exhibited a jump in tau from preseason levels compared to their short RTP counterparts. Statistical analyses showed that higher blood tau concentrations 6 hours post-concussion consistently predicted that an athlete would take more than 10 days to resume play.
“This study suggests that tau may be a useful biomarker for identifying athletes who may take longer to recover after a concussion,” said Prof. Bazarian, “Athletes are typically eager to get back to play as soon as possible and may tell doctors that they’re better even when they’re not. Tau is an unbiased measurement that can’t be gamed, athletes can’t fake it. It may be that tau combined with current clinical assessments could help us make more informed RTP decisions and prevent players from going back to a contact sport when their brains are still healing.”
The study included both male and female athletes and showed that tau-related changes occurred in both genders across a variety of sports. The team found significant differences based on sex: women made up 61% of the long RTP group, but only 28% of the short RTP group. Prof. Bazarian said this isn’t surprising – it is well established that females take longer to recover following concussion than males.
The researchers acknowledge that the study is limited by its small size and that more research is needed to determine if tau can be established as a biomarker of concussion severity and/or recovery. Next steps include getting blood samples from athletes immediately following a concussion to see if the relationship between tau and RTP observed in the study holds true also on the sideline in the first few minutes following a head hit.
The study, by Gill J et al, was published in the January 6, 2017, issue of the journal Neurology.
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







